Inspirna
Inspirna (formerly Rgenix) is a privately-held cancer therapeutics company focused on the discovery and development of novel cancer drugs that target key pathways in cancer progression. Using a mRNA-based target discovery platform developed by Inspirna's scientific co-founders at The Rockefeller University, the company is developing several first-in-class drug candidates to treat cancers of high unmet need. The company brings together distinguished scientific founders and a leadership team with a seasoned Board comprised of experienced drug developers. The company is funded by leading biotechnology investors, including Novo A/S, Sofinnova Partners, and Alexandria Venture Investments.
Sector
Biopharmaceuticals
Strategy
Status
Live
Website
inspirna.com
Related News
Inspirna Partners with Merck KGaA, Darmstadt, Germany, to accelerate global development of Ompenaclid (RGX-202)
Inspirna appoints Dr. Usman “Oz” Azam, M.D., as new Chief Executive Officer
Inspirna announces interim data from Phase 1b/2 study of Abequolixron (RGX-104) in relapsed or refractory lung cancer
Inspirna raises $50 million in Series D financing
Inspirna to present Phase 1b RGX-202-01 clinical trial data at the 2022 ESMO World Congress on Gastrointestinal Cancer
SofinnovaCapital
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
SofinnovaMD Start
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
SofinnovaDigital Medicine
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.